Stockscreener 앱 받기
40.62
0.56%
-0.23
시간 외 거래:
40.62
전일 마감가:
$40.85
열려 있는:
$40.67
하루 거래량:
840.55K
Relative Volume:
1.01
시가총액:
$2.65B
수익:
$58.89M
순이익/손실:
$-240.88M
주가수익비율:
-13.10
EPS:
-3.1
순현금흐름:
$-239.96M
1주 성능:
-5.45%
1개월 성능:
-6.47%
6개월 성능:
+8.84%
1년 성능:
-3.31%
1일 변동 폭
$39.54
$40.91
1주일 범위
$39.54
$43.84
52주 변동 폭
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5314
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
40.62 | 2.90B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-20 | 재개 | Stifel | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Market Perform |
| 2024-12-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-26 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 개시 | Oppenheimer | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 개시 | Truist | Buy |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 개시 | Raymond James | Mkt Perform |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-08-03 | 개시 | Goldman | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | JP Morgan | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2021-09-30 | 개시 | B. Riley Securities | Neutral |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-09-15 | 개시 | BofA Securities | Neutral |
| 2020-09-15 | 개시 | Cowen | Outperform |
| 2020-09-15 | 개시 | Guggenheim | Buy |
| 2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit - MSN
Kymera Therapeutics Earnings Preview: What to Expect - AInvest
Kymera Therapeutics KYMR Q2 2025 Earnings Preview Upside Potential Driven by Strategic Partnerships - AInvest
Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result - Yahoo Finance
Kymera Therapeutics Becomes Oversold (KYMR) - Nasdaq
Earnings Preview: KYMR to Report Financial Results Pre-market on August 11 - 富途牛牛
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 - The Manila Times
Kymera Therapeutics reports Q2 2025 results, plans call on August 11. - AInvest
Clinical-Stage Biotech Kymera Therapeutics Sets Q2 Earnings Date: Key Updates Expected on Immunology Pipeline - Stock Titan
Is Kymera Therapeutics Inc. a growth stock or a value stockFree Investment Community - Jammu Links News
How does Kymera Therapeutics Inc. generate profit in a changing economyTransform your portfolio with high-yield stocks - Jammu Links News
What catalysts could drive Kymera Therapeutics Inc. stock higher in 2025Get expert analysis on top stock picks - Jammu Links News
What makes Kymera Therapeutics Inc. stock price move sharplyAchieve consistent profits with proven methods - Jammu Links News
Should I hold or sell Kymera Therapeutics Inc. stock in 2025Dynamic portfolio growth - Jammu Links News
How many analysts rate Kymera Therapeutics Inc. as a “Buy”Stay ahead with daily market updates - Jammu Links News
Why is Kymera Therapeutics Inc. stock attracting strong analyst attentionUnlock powerful trading tools for investors - Jammu Links News
What is Kymera Therapeutics Inc. company’s growth strategyExplosive earning power - Jammu Links News
What analysts say about Kymera Therapeutics Inc. stockCapitalize on emerging trends for profits - Jammu Links News
How strong is Kymera Therapeutics Inc. company’s balance sheetSwing Trade Review With Proven Results - Jammu Links News
Kymera Therapeutics: A Biotech Company with a Promising Future - AInvest
Is it the right time to buy Kymera Therapeutics Inc. stockBreakout Stocks Ideas For 2025 - Jammu Links News
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer - MSN
Kymera Therapeutics Inc. Chart Enters High Volatility ZoneSecure Return Focused Investment Plan Released - metal.it
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Published on: 2025-07-29 17:18:26 - metal.it
How did KYMR's Q1 2025 EPS forecast compare to past trends? - AInvest
What analysts say about Kymera Therapeutics Inc. stock outlookMarket Surge Signal for Swing Traders Triggered - metal.it
How volatile is Kymera Therapeutics Inc. stock compared to the marketAchieve breakthrough results with expert guidance - Jammu Links News
What are Kymera Therapeutics Inc. company’s key revenue driversFast-track wealth growth - Jammu Links News
Does Kymera Therapeutics Inc. stock perform well during market downturnsUnlock your trading potential today - Jammu Links News
Kymera Therapeutics Inc. Stock Analysis and ForecastSuperior returns - PrintWeekIndia
Will Kymera Therapeutics Inc. stock benefit from AI tech trendsOutstanding trading profits - jammulinksnews.com
What drives Kymera Therapeutics Inc. stock priceOutstanding growth strategies - PrintWeekIndia
Is Kymera Therapeutics Inc. a good long term investmentFree Stock Market Query - Autocar Professional
Kymera Therapeutics Inc (KYMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):